RxDoctor Payments Data

Hassanatu Michael, NP

Psychiatric/Mental Health · Mesquite, TXNPI 1861892333

Payments from drug & device makers

$3,135in general payments, 2019–2025

Across 169 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$751
  • Neurocrine Biosciences, Inc.$581
  • Sunovion Pharmaceuticals Inc.$369
  • Otsuka America Pharmaceutical, Inc.$268
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$258
  • Johnson & Johnson$224
  • plus $685 from 9 others

What the payments were for

  • Food & beverage$3,01396%
  • Education$1224%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,135 in reported general payments places this provider in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$35,149
Medicare patients
21
Services billed
423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate63$505,565
AustedoDeutetrabenazine40$264,643
VraylarCariprazine Hcl88$134,670
LatudaLurasidone Hcl18$24,690
Abilify MaintenaAripiprazole11$22,888
Lurasidone Hcl94$15,416
Aripiprazole145$11,108
Quetiapine Fumarate166$4,081
Trazodone Hcl219$3,831
Duloxetine Hcl91$3,252
Buspirone Hcl227$2,811
Hydroxyzine Hcl170$2,802
Ziprasidone Hcl49$2,615
Doxepin Hcl96$2,157
Olanzapine51$1,409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$581$505,56563 claims
Teva Pharmaceuticals USA, Inc.Austedo$162$264,64340 claims
AbbVieVraylar$751$134,67088 claims
Sunovion Pharmaceuticals Inc.Latuda$369$24,69018 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$268$22,88811 claims
Almatica Pharma LLCSertraline Hcl$43$47691 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Mesquite

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →